APO Research
Talk to an analyst

APO RESEARCH · REPORT

Contact-lens Induced Infection

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Contact-lens Induced Infection Market Analysis and Forecast 2026-2032

29 December 2025199 pages

Choose your research edition.

Industry ResearchContact-lens Induced Infection Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Contact-lens Induced Infection Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Contact-lens Induced Infection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Contact-lens Induced Infection Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Contact-lens Induced Infection Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Contact-lens Induced Infection market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Contact-lens Induced Infection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Contact-lens Induced Infection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Contact-lens Induced Infection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Contact-lens Induced Infection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Contact-lens Induced Infection include Teva Pharmaceutical, Merck & Co., Pfizer, Alcon, AbbVie, Shionogi, Santen Pharmaceutical, Roche Holding and Otsuka Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Contact-lens Induced Infection, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Contact-lens Induced Infection, also provides the revenue of main regions and countries. Of the upcoming market potential for Contact-lens Induced Infection, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Contact-lens Induced Infection revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Contact-lens Induced Infection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Contact-lens Induced Infection revenue, projected growth trends, production technology, application and end-user industry.

Contact-lens Induced Infection Segment by Company

Teva Pharmaceutical

Merck & Co.

Pfizer

Alcon

AbbVie

Shionogi

Santen Pharmaceutical

Roche Holding

Otsuka Pharmaceutical

Novartis International

Kowa Company

Hikma Pharmaceuticals

Dr. Reddy’s Laboratories

Bausch + Lomb

AstraZeneca

Contact-lens Induced Infection Segment by Type

Corticosteroids

Anti-inflammatory Drugs

Antibiotics

NSAIDs

Other

Contact-lens Induced Infection Segment by Application

Retail Pharmacy

Ophthalmology Clinics

Hospitals

Other

Contact-lens Induced Infection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Contact-lens Induced Infection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Contact-lens Induced Infection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Contact-lens Induced Infection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Contact-lens Induced Infection in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Contact-lens Induced Infection company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Contact-lens Induced Infection revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Contact-lens Induced Infection Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Corticosteroids Major Player Table 3. Anti-inflammatory Drugs Major Player Table 4. Antibiotics Major Player Table 5. NSAIDs Major Player Table 6. Other Major Player Table 7. Global Contact-lens Induced Infection Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Retail Pharmacy Major Player Table 9. Ophthalmology Clinics Major Player Table 10. Hospitals Major Player Table 11. Other Major Player Table 12. Contact-lens Induced Infection Industry Trends Table 13. Contact-lens Induced Infection Industry Drivers Table 14. Contact-lens Induced Infection Industry Opportunities and Challenges Table 15. Contact-lens Induced Infection Industry Restraints Table 16. Global Contact-lens Induced Infection Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Contact-lens Induced Infection Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Contact-lens Induced Infection Market Share by Region (2021-2026) Table 19. Global Contact-lens Induced Infection Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Contact-lens Induced Infection Market Share by Region (2027-2032) Table 21. Global Contact-lens Induced Infection Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Contact-lens Induced Infection Revenue Market Share by Players (2021-2026) Table 23. Global Contact-lens Induced Infection Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Contact-lens Induced Infection Key Players Headquarters & Area Served Table 25. Global Contact-lens Induced Infection Players, Product Type & Application Table 26. Global Contact-lens Induced Infection Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Contact-lens Induced Infection by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Contact-lens Induced Infection Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Contact-lens Induced Infection Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Contact-lens Induced Infection Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Contact-lens Induced Infection Revenue Market Share by Type (2021-2026) Table 33. Global Contact-lens Induced Infection Revenue Market Share by Type (2027-2032) Table 34. Global Contact-lens Induced Infection Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Contact-lens Induced Infection Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Contact-lens Induced Infection Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Contact-lens Induced Infection Revenue Market Share by Application (2021-2026) Table 38. Global Contact-lens Induced Infection Revenue Market Share by Application (2027-2032) Table 39. Teva Pharmaceutical Company Information Table 40. Teva Pharmaceutical Business Overview Table 41. Teva Pharmaceutical Contact-lens Induced Infection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Teva Pharmaceutical Contact-lens Induced Infection Product Portfolio Table 43. Teva Pharmaceutical Recent Development Table 44. Merck & Co. Company Information Table 45. Merck & Co. Business Overview Table 46. Merck & Co. Contact-lens Induced Infection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Merck & Co. Contact-lens Induced Infection Product Portfolio Table 48. Merck & Co. Recent Development Table 49. Pfizer Company Information Table 50. Pfizer Business Overview Table 51. Pfizer Contact-lens Induced Infection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Pfizer Contact-lens Induced Infection Product Portfolio Table 53. Pfizer Recent Development Table 54. Alcon Company Information Table 55. Alcon Business Overview Table 56. Alcon Contact-lens Induced Infection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Alcon Contact-lens Induced Infection Product Portfolio Table 58. Alcon Recent Development Table 59. AbbVie Company Information Table 60. AbbVie Business Overview Table 61. AbbVie Contact-lens Induced Infection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. AbbVie Contact-lens Induced Infection Product Portfolio Table 63. AbbVie Recent Development Table 64. Shionogi Company Information Table 65. Shionogi Business Overview Table 66. Shionogi Contact-lens Induced Infection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Shionogi Contact-lens Induced Infection Product Portfolio Table 68. Shionogi Recent Development Table 69. Santen Pharmaceutical Company Information Table 70. Santen Pharmaceutical Business Overview Table 71. Santen Pharmaceutical Contact-lens Induced Infection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Santen Pharmaceutical Contact-lens Induced Infection Product Portfolio Table 73. Santen Pharmaceutical Recent Development Table 74. Roche Holding Company Information Table 75. Roche Holding Business Overview Table 76. Roche Holding Contact-lens Induced Infection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Roche Holding Contact-lens Induced Infection Product Portfolio Table 78. Roche Holding Recent Development Table 79. Otsuka Pharmaceutical Company Information Table 80. Otsuka Pharmaceutical Business Overview Table 81. Otsuka Pharmaceutical Contact-lens Induced Infection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Otsuka Pharmaceutical Contact-lens Induced Infection Product Portfolio Table 83. Otsuka Pharmaceutical Recent Development Table 84. Novartis International Company Information Table 85. Novartis International Business Overview Table 86. Novartis International Contact-lens Induced Infection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Novartis International Contact-lens Induced Infection Product Portfolio Table 88. Novartis International Recent Development Table 89. Kowa Company Company Information Table 90. Kowa Company Business Overview Table 91. Kowa Company Contact-lens Induced Infection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Kowa Company Contact-lens Induced Infection Product Portfolio Table 93. Kowa Company Recent Development Table 94. Hikma Pharmaceuticals Company Information Table 95. Hikma Pharmaceuticals Business Overview Table 96. Hikma Pharmaceuticals Contact-lens Induced Infection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Hikma Pharmaceuticals Contact-lens Induced Infection Product Portfolio Table 98. Hikma Pharmaceuticals Recent Development Table 99. Dr. Reddy’s Laboratories Company Information Table 100. Dr. Reddy’s Laboratories Business Overview Table 101. Dr. Reddy’s Laboratories Contact-lens Induced Infection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Dr. Reddy’s Laboratories Contact-lens Induced Infection Product Portfolio Table 103. Dr. Reddy’s Laboratories Recent Development Table 104. Bausch + Lomb Company Information Table 105. Bausch + Lomb Business Overview Table 106. Bausch + Lomb Contact-lens Induced Infection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Bausch + Lomb Contact-lens Induced Infection Product Portfolio Table 108. Bausch + Lomb Recent Development Table 109. AstraZeneca Company Information Table 110. AstraZeneca Business Overview Table 111. AstraZeneca Contact-lens Induced Infection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. AstraZeneca Contact-lens Induced Infection Product Portfolio Table 113. AstraZeneca Recent Development Table 114. North America Contact-lens Induced Infection Revenue by Type (2021-2026) & (US$ Million) Table 115. North America Contact-lens Induced Infection Revenue by Type (2027-2032) & (US$ Million) Table 116. North America Contact-lens Induced Infection Revenue by Application (2021-2026) & (US$ Million) Table 117. North America Contact-lens Induced Infection Revenue by Application (2027-2032) & (US$ Million) Table 118. North America Contact-lens Induced Infection Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. North America Contact-lens Induced Infection Revenue by Country (2021-2026) & (US$ Million) Table 120. North America Contact-lens Induced Infection Revenue by Country (US$ Million) & (2027-2032) Table 121. Europe Contact-lens Induced Infection Revenue by Type (2021-2026) & (US$ Million) Table 122. Europe Contact-lens Induced Infection Revenue by Type (2027-2032) & (US$ Million) Table 123. Europe Contact-lens Induced Infection Revenue by Application (2021-2026) & (US$ Million) Table 124. Europe Contact-lens Induced Infection Revenue by Application (2027-2032) & (US$ Million) Table 125. Europe Contact-lens Induced Infection Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. Europe Contact-lens Induced Infection Revenue by Country (2021-2026) & (US$ Million) Table 127. Europe Contact-lens Induced Infection Revenue by Country (US$ Million) & (2027-2032) Table 128. China Contact-lens Induced Infection Revenue by Type (2021-2026) & (US$ Million) Table 129. China Contact-lens Induced Infection Revenue by Type (2027-2032) & (US$ Million) Table 130. China Contact-lens Induced Infection Revenue by Application (2021-2026) & (US$ Million) Table 131. China Contact-lens Induced Infection Revenue by Application (2027-2032) & (US$ Million) Table 132. Asia Contact-lens Induced Infection Revenue by Type (2021-2026) & (US$ Million) Table 133. Asia Contact-lens Induced Infection Revenue by Type (2027-2032) & (US$ Million) Table 134. Asia Contact-lens Induced Infection Revenue by Application (2021-2026) & (US$ Million) Table 135. Asia Contact-lens Induced Infection Revenue by Application (2027-2032) & (US$ Million) Table 136. Asia Contact-lens Induced Infection Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 137. Asia Contact-lens Induced Infection Revenue by Region (US$ Million) & (2021-2026) Table 138. Asia Contact-lens Induced Infection Revenue by Region (US$ Million) & (2027-2032) Table 139. SAMEA Contact-lens Induced Infection Revenue by Type (2021-2026) & (US$ Million) Table 140. SAMEA Contact-lens Induced Infection Revenue by Type (2027-2032) & (US$ Million) Table 141. SAMEA Contact-lens Induced Infection Revenue by Application (2021-2026) & (US$ Million) Table 142. SAMEA Contact-lens Induced Infection Revenue by Application (2027-2032) & (US$ Million) Table 143. SAMEA Contact-lens Induced Infection Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. SAMEA Contact-lens Induced Infection Revenue by Country (2021-2026) & (US$ Million) Table 145. SAMEA Contact-lens Induced Infection Revenue by Country (US$ Million) & (2027-2032) Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Contact-lens Induced Infection Image Figure 2. Global Contact-lens Induced Infection Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Contact-lens Induced Infection Market Size Share 2021 VS 2025 VS 2032 Figure 4. Corticosteroids Image Figure 5. Anti-inflammatory Drugs Image Figure 6. Antibiotics Image Figure 7. NSAIDs Image Figure 8. Other Image Figure 9. Global Contact-lens Induced Infection Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Contact-lens Induced Infection Market Size Share 2021 VS 2025 VS 2032 Figure 11. Retail Pharmacy Image Figure 12. Ophthalmology Clinics Image Figure 13. Hospitals Image Figure 14. Other Image Figure 15. Global Contact-lens Induced Infection Market Size (US$ Million) & (2021-2032) Figure 16. Global Contact-lens Induced Infection Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Contact-lens Induced Infection Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Contact-lens Induced Infection Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Contact-lens Induced Infection Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Contact-lens Induced Infection Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Contact-lens Induced Infection Revenue Market Share by Type (2021-2032) Figure 23. Global Contact-lens Induced Infection Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Contact-lens Induced Infection Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Contact-lens Induced Infection Revenue Market Share by Application (2021-2032) Figure 26. North America Contact-lens Induced Infection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Contact-lens Induced Infection Revenue Share by Type (2021-2032) Figure 28. North America Contact-lens Induced Infection Revenue Share by Application (2021-2032) Figure 29. North America Contact-lens Induced Infection Revenue Share by Country (2021-2032) Figure 30. United States Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Contact-lens Induced Infection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Contact-lens Induced Infection Revenue Share by Type (2021-2032) Figure 35. Europe Contact-lens Induced Infection Revenue Share by Application (2021-2032) Figure 36. Europe Contact-lens Induced Infection Revenue Share by Country (2021-2032) Figure 37. Germany Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Contact-lens Induced Infection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Contact-lens Induced Infection Revenue Share by Type (2021-2032) Figure 47. China Contact-lens Induced Infection Revenue Share by Application (2021-2032) Figure 48. Asia Contact-lens Induced Infection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Contact-lens Induced Infection Revenue Share by Type (2021-2032) Figure 50. Asia Contact-lens Induced Infection Revenue Share by Application (2021-2032) Figure 51. Asia Contact-lens Induced Infection Revenue Share by Region (2021-2032) Figure 52. Japan Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Contact-lens Induced Infection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Contact-lens Induced Infection Revenue Share by Type (2021-2032) Figure 60. SAMEA Contact-lens Induced Infection Revenue Share by Application (2021-2032) Figure 61. SAMEA Contact-lens Induced Infection Revenue Share by Country (2021-2032) Figure 62. Brazil Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Contact-lens Induced Infection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Corticosteroids
  • Anti-inflammatory Drugs
  • Antibiotics
  • NSAIDs
  • Other
Applications
  • Retail Pharmacy
  • Ophthalmology Clinics
  • Hospitals
  • Other
Companies covered
  • Teva Pharmaceutical
  • Merck & Co.
  • Pfizer
  • Alcon
  • AbbVie
  • Shionogi
  • Santen Pharmaceutical
  • Roche Holding
  • Otsuka Pharmaceutical
  • Novartis International
  • Kowa Company
  • Hikma Pharmaceuticals
  • Dr. Reddy’s Laboratories
  • Bausch + Lomb
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Contact-lens Induced Infection Market by Type
  3. 1.2.1 Global Contact-lens Induced Infection Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Corticosteroids
  5. 1.2.3 Anti-inflammatory Drugs
  6. 1.2.4 Antibiotics
  7. 1.2.5 NSAIDs
  8. 1.2.6 Other
  9. 1.3 Contact-lens Induced Infection Market by Application
  10. 1.3.1 Global Contact-lens Induced Infection Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Retail Pharmacy
  12. 1.3.3 Ophthalmology Clinics
  13. 1.3.4 Hospitals
  14. 1.3.5 Other
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Contact-lens Induced Infection Market Dynamics
  1. 2.1 Contact-lens Induced Infection Industry Trends
  2. 2.2 Contact-lens Induced Infection Industry Drivers
  3. 2.3 Contact-lens Induced Infection Industry Opportunities and Challenges
  4. 2.4 Contact-lens Induced Infection Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Contact-lens Induced Infection Market Perspective (2021-2032)
  2. 3.2 Global Contact-lens Induced Infection Growth Trends by Region
  3. 3.2.1 Global Contact-lens Induced Infection Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Contact-lens Induced Infection Market Size by Region (2021-2026)
  5. 3.2.3 Global Contact-lens Induced Infection Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Contact-lens Induced Infection Revenue by Players
  2. 4.1.1 Global Contact-lens Induced Infection Revenue by Players (2021-2026)
  3. 4.1.2 Global Contact-lens Induced Infection Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Contact-lens Induced Infection Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Contact-lens Induced Infection Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Contact-lens Induced Infection Key Players Headquarters & Area Served
  7. 4.4 Global Contact-lens Induced Infection Players, Product Type & Application
  8. 4.5 Global Contact-lens Induced Infection Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Contact-lens Induced Infection Market CR5 and HHI
  11. 4.6.3 2025 Contact-lens Induced Infection Tier 1, Tier 2, and Tier 3
5 Contact-lens Induced Infection Market Size by Type
  1. 5.1 Global Contact-lens Induced Infection Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Contact-lens Induced Infection Revenue by Type (2021-2032)
  3. 5.3 Global Contact-lens Induced Infection Revenue Market Share by Type (2021-2032)
6 Contact-lens Induced Infection Market Size by Application
  1. 6.1 Global Contact-lens Induced Infection Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Contact-lens Induced Infection Revenue by Application (2021-2032)
  3. 6.3 Global Contact-lens Induced Infection Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva Pharmaceutical
  2. 7.1.1 Teva Pharmaceutical Company Information
  3. 7.1.2 Teva Pharmaceutical Business Overview
  4. 7.1.3 Teva Pharmaceutical Contact-lens Induced Infection Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Pharmaceutical Contact-lens Induced Infection Product Portfolio
  6. 7.1.5 Teva Pharmaceutical Recent Developments
  7. 7.2 Merck & Co.
  8. 7.2.1 Merck & Co. Company Information
  9. 7.2.2 Merck & Co. Business Overview
  10. 7.2.3 Merck & Co. Contact-lens Induced Infection Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck & Co. Contact-lens Induced Infection Product Portfolio
  12. 7.2.5 Merck & Co. Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Contact-lens Induced Infection Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Contact-lens Induced Infection Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 Alcon
  20. 7.4.1 Alcon Company Information
  21. 7.4.2 Alcon Business Overview
  22. 7.4.3 Alcon Contact-lens Induced Infection Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Alcon Contact-lens Induced Infection Product Portfolio
  24. 7.4.5 Alcon Recent Developments
  25. 7.5 AbbVie
  26. 7.5.1 AbbVie Company Information
  27. 7.5.2 AbbVie Business Overview
  28. 7.5.3 AbbVie Contact-lens Induced Infection Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AbbVie Contact-lens Induced Infection Product Portfolio
  30. 7.5.5 AbbVie Recent Developments
  31. 7.6 Shionogi
  32. 7.6.1 Shionogi Company Information
  33. 7.6.2 Shionogi Business Overview
  34. 7.6.3 Shionogi Contact-lens Induced Infection Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Shionogi Contact-lens Induced Infection Product Portfolio
  36. 7.6.5 Shionogi Recent Developments
  37. 7.7 Santen Pharmaceutical
  38. 7.7.1 Santen Pharmaceutical Company Information
  39. 7.7.2 Santen Pharmaceutical Business Overview
  40. 7.7.3 Santen Pharmaceutical Contact-lens Induced Infection Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Santen Pharmaceutical Contact-lens Induced Infection Product Portfolio
  42. 7.7.5 Santen Pharmaceutical Recent Developments
  43. 7.8 Roche Holding
  44. 7.8.1 Roche Holding Company Information
  45. 7.8.2 Roche Holding Business Overview
  46. 7.8.3 Roche Holding Contact-lens Induced Infection Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Roche Holding Contact-lens Induced Infection Product Portfolio
  48. 7.8.5 Roche Holding Recent Developments
  49. 7.9 Otsuka Pharmaceutical
  50. 7.9.1 Otsuka Pharmaceutical Company Information
  51. 7.9.2 Otsuka Pharmaceutical Business Overview
  52. 7.9.3 Otsuka Pharmaceutical Contact-lens Induced Infection Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Otsuka Pharmaceutical Contact-lens Induced Infection Product Portfolio
  54. 7.9.5 Otsuka Pharmaceutical Recent Developments
  55. 7.10 Novartis International
  56. 7.10.1 Novartis International Company Information
  57. 7.10.2 Novartis International Business Overview
  58. 7.10.3 Novartis International Contact-lens Induced Infection Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Novartis International Contact-lens Induced Infection Product Portfolio
  60. 7.10.5 Novartis International Recent Developments
  61. 7.11 Kowa Company
  62. 7.11.1 Kowa Company Company Information
  63. 7.11.2 Kowa Company Business Overview
  64. 7.11.3 Kowa Company Contact-lens Induced Infection Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Kowa Company Contact-lens Induced Infection Product Portfolio
  66. 7.11.5 Kowa Company Recent Developments
  67. 7.12 Hikma Pharmaceuticals
  68. 7.12.1 Hikma Pharmaceuticals Company Information
  69. 7.12.2 Hikma Pharmaceuticals Business Overview
  70. 7.12.3 Hikma Pharmaceuticals Contact-lens Induced Infection Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Hikma Pharmaceuticals Contact-lens Induced Infection Product Portfolio
  72. 7.12.5 Hikma Pharmaceuticals Recent Developments
  73. 7.13 Dr. Reddy’s Laboratories
  74. 7.13.1 Dr. Reddy’s Laboratories Company Information
  75. 7.13.2 Dr. Reddy’s Laboratories Business Overview
  76. 7.13.3 Dr. Reddy’s Laboratories Contact-lens Induced Infection Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Dr. Reddy’s Laboratories Contact-lens Induced Infection Product Portfolio
  78. 7.13.5 Dr. Reddy’s Laboratories Recent Developments
  79. 7.14 Bausch + Lomb
  80. 7.14.1 Bausch + Lomb Company Information
  81. 7.14.2 Bausch + Lomb Business Overview
  82. 7.14.3 Bausch + Lomb Contact-lens Induced Infection Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Bausch + Lomb Contact-lens Induced Infection Product Portfolio
  84. 7.14.5 Bausch + Lomb Recent Developments
  85. 7.15 AstraZeneca
  86. 7.15.1 AstraZeneca Company Information
  87. 7.15.2 AstraZeneca Business Overview
  88. 7.15.3 AstraZeneca Contact-lens Induced Infection Revenue and Gross Margin (2021-2026)
  89. 7.15.4 AstraZeneca Contact-lens Induced Infection Product Portfolio
  90. 7.15.5 AstraZeneca Recent Developments
8 North America
  1. 8.1 North America Contact-lens Induced Infection Revenue (2021-2032)
  2. 8.2 North America Contact-lens Induced Infection Revenue by Type (2021-2032)
  3. 8.2.1 North America Contact-lens Induced Infection Revenue by Type (2021-2026)
  4. 8.2.2 North America Contact-lens Induced Infection Revenue by Type (2027-2032)
  5. 8.3 North America Contact-lens Induced Infection Revenue Share by Type (2021-2032)
  6. 8.4 North America Contact-lens Induced Infection Revenue by Application (2021-2032)
  7. 8.4.1 North America Contact-lens Induced Infection Revenue by Application (2021-2026)
  8. 8.4.2 North America Contact-lens Induced Infection Revenue by Application (2027-2032)
  9. 8.5 North America Contact-lens Induced Infection Revenue Share by Application (2021-2032)
  10. 8.6 North America Contact-lens Induced Infection Revenue by Country
  11. 8.6.1 North America Contact-lens Induced Infection Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Contact-lens Induced Infection Revenue by Country (2021-2026)
  13. 8.6.3 North America Contact-lens Induced Infection Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Contact-lens Induced Infection Revenue (2021-2032)
  2. 9.2 Europe Contact-lens Induced Infection Revenue by Type (2021-2032)
  3. 9.2.1 Europe Contact-lens Induced Infection Revenue by Type (2021-2026)
  4. 9.2.2 Europe Contact-lens Induced Infection Revenue by Type (2027-2032)
  5. 9.3 Europe Contact-lens Induced Infection Revenue Share by Type (2021-2032)
  6. 9.4 Europe Contact-lens Induced Infection Revenue by Application (2021-2032)
  7. 9.4.1 Europe Contact-lens Induced Infection Revenue by Application (2021-2026)
  8. 9.4.2 Europe Contact-lens Induced Infection Revenue by Application (2027-2032)
  9. 9.5 Europe Contact-lens Induced Infection Revenue Share by Application (2021-2032)
  10. 9.6 Europe Contact-lens Induced Infection Revenue by Country
  11. 9.6.1 Europe Contact-lens Induced Infection Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Contact-lens Induced Infection Revenue by Country (2021-2026)
  13. 9.6.3 Europe Contact-lens Induced Infection Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Contact-lens Induced Infection Revenue (2021-2032)
  2. 10.2 China Contact-lens Induced Infection Revenue by Type (2021-2032)
  3. 10.2.1 China Contact-lens Induced Infection Revenue by Type (2021-2026)
  4. 10.2.2 China Contact-lens Induced Infection Revenue by Type (2027-2032)
  5. 10.3 China Contact-lens Induced Infection Revenue Share by Type (2021-2032)
  6. 10.4 China Contact-lens Induced Infection Revenue by Application (2021-2032)
  7. 10.4.1 China Contact-lens Induced Infection Revenue by Application (2021-2026)
  8. 10.4.2 China Contact-lens Induced Infection Revenue by Application (2027-2032)
  9. 10.5 China Contact-lens Induced Infection Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Contact-lens Induced Infection Revenue (2021-2032)
  2. 11.2 Asia Contact-lens Induced Infection Revenue by Type (2021-2032)
  3. 11.2.1 Asia Contact-lens Induced Infection Revenue by Type (2021-2026)
  4. 11.2.2 Asia Contact-lens Induced Infection Revenue by Type (2027-2032)
  5. 11.3 Asia Contact-lens Induced Infection Revenue Share by Type (2021-2032)
  6. 11.4 Asia Contact-lens Induced Infection Revenue by Application (2021-2032)
  7. 11.4.1 Asia Contact-lens Induced Infection Revenue by Application (2021-2026)
  8. 11.4.2 Asia Contact-lens Induced Infection Revenue by Application (2027-2032)
  9. 11.5 Asia Contact-lens Induced Infection Revenue Share by Application (2021-2032)
  10. 11.6 Asia Contact-lens Induced Infection Revenue by Country
  11. 11.6.1 Asia Contact-lens Induced Infection Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Contact-lens Induced Infection Revenue by Country (2021-2026)
  13. 11.6.3 Asia Contact-lens Induced Infection Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Contact-lens Induced Infection Revenue (2021-2032)
  2. 12.2 SAMEA Contact-lens Induced Infection Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Contact-lens Induced Infection Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Contact-lens Induced Infection Revenue by Type (2027-2032)
  5. 12.3 SAMEA Contact-lens Induced Infection Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Contact-lens Induced Infection Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Contact-lens Induced Infection Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Contact-lens Induced Infection Revenue by Application (2027-2032)
  9. 12.5 SAMEA Contact-lens Induced Infection Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Contact-lens Induced Infection Revenue by Country
  11. 12.6.1 SAMEA Contact-lens Induced Infection Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Contact-lens Induced Infection Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Contact-lens Induced Infection Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst